Market News

Arcturus Therapeutics Ltd. (ARCT) Reaches $5.37 52-Week Low; Hbk Investments LP Raised Csx (CSX) Holding

Hbk Investments LP increased Csx Corp (CSX) stake by 82.01% reported in 2017Q3 SEC filing. Hbk Investments LP acquired 115,223 shares as Csx Corp (CSX)’s stock rose 3.79%. The Hbk Investments LP holds 255,717 shares with $13.88M value, up from 140,494 last quarter. Csx Corp now has $45.48B valuation. The stock increased 0.83% or $0.42 during the last trading session, reaching $50.89. About 12.28 million shares traded or 53.29% up from the average. CSX Corporation (NYSE:CSX) has risen 97.18% since February 11, 2017 and is uptrending. It has outperformed by 80.48% the S&P500.

The stock of Arcturus Therapeutics Ltd. (NASDAQ:ARCT) hit a new 52-week low and has $5.05 target or 6.00% below today’s $5.37 share price. The 5 months bearish chart indicates high risk for the $ company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $5.05 price target is reached, the company will be worth $ less. The stock decreased 9.38% or $0.56 during the last trading session, reaching $5.37. About 128,915 shares traded or 55.95% up from the average. Arcturus Therapeutics Ltd. (NASDAQ:ARCT) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. The company has market cap of $. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It currently has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

Among 31 analysts covering CSX Corporation (NYSE:CSX), 19 have Buy rating, 3 Sell and 9 Hold. Therefore 61% are positive. CSX Corporation had 102 analyst reports since August 13, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, October 18. The rating was maintained by BMO Capital Markets with “Buy” on Monday, April 24. As per Friday, December 15, the company rating was maintained by RBC Capital Markets. The firm has “Underweight” rating by Morgan Stanley given on Tuesday, February 23. The stock of CSX Corporation (NASDAQ:CSX) earned “Overweight” rating by Barclays Capital on Wednesday, October 18. The firm has “Buy” rating given on Wednesday, March 1 by Deutsche Bank. The firm earned “Buy” rating on Friday, August 11 by RBC Capital Markets. Scotia Capital downgraded CSX Corporation (NASDAQ:CSX) on Friday, January 12 to “Sector Perform” rating. Bank of America downgraded CSX Corporation (NASDAQ:CSX) rating on Friday, December 4. Bank of America has “Neutral” rating and $29 target. Stifel Nicolaus maintained the stock with “Hold” rating in Tuesday, October 17 report.

Hbk Investments LP decreased Changyou Com Ltd (NASDAQ:CYOU) stake by 24,455 shares to 8,945 valued at $354,000 in 2017Q3. It also reduced Abm Inds Inc (NYSE:ABM) stake by 10,800 shares and now owns 9,500 shares. Entegris Inc (NASDAQ:ENTG) was reduced too.

Leave a Reply

Your email address will not be published. Required fields are marked *